Sernova Biotherapeutics Inc. is a Canada-based clinical-stage company, which is focused on developing regenerative medicine therapeutics combining its Cell Pouch with human donor cells or stem cell-derived cell therapies to create bio-hybrid organs to treat chronic diseases. A bio-hybrid organ is comprised of non-biomaterials, such as the Cell Pouch, integrated with living tissues to restore or enhance the function of a compromised organ. This approach aims to deliver a potentially revolutionary treatment for patients with chronic diseases, initially focusing on type 1 diabetes (T1D) and thyroid disorders. Cell Pouch is a bio-hybrid organ which is surgically implanted beneath the skin of the abdomen.

Employees

Sector

Medical Equipment, Supplies & Distribution

More about the company

Quotes

Date	Price	Change
26-10-02	CA$0.1050	-4.55%
26-10-01	CA$0.1100	+4.76%
26-09-30	CA$0.1050	+16.67%
26-09-29	CA$0.0900	0.00%
26-09-28	CA$0.0900	0.00%

Delayed Quote Toronto S.E.

More quotes

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

0.1050CAD

Average target price

1.000CAD

Spread / Average Target

+852.38%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Toronto S.E. 10:30:05 2026-10-02 am EDT			5-day change	1st Jan Change
0.1050 ^CAD	-4.55%		+16.67%	-19.23%

Sep. 10	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
Sep. 08	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI

Market Cap	39.65M 27.82M 24.71M 23.07M 21.02M 2.67B 40.02M 279M 108M 1.37B 104M 102M 4.39B	P/E 2026 *	-4.2x	P/E 2027 *	-3.5x
Enterprise Value	39.65M 27.82M 24.71M 23.07M 21.02M 2.67B 40.02M 279M 108M 1.37B 104M 102M 4.39B	EV / Sales 2026 *	-	EV / Sales 2027 *	15.9x
Free-Float	89.49%	Yield 2026 *	-	Yield 2027 *	-

Markets		Quality
Toronto S.E.	SVA	End-of-day quote
OTC Markets	SEOVF	Delayed
Xetra	PSH0	Delayed
Toronto S.E.	SVA	Delayed
Tradegate	PSH0	Real-time
Deutsche Boerse AG	PSH0	Delayed
Börse Stuttgart	PSH0	Delayed
Boerse Muenchen	PSH0	Real-time

Sep. 10	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2026	CI
Sep. 08	Seraxis Holdings, Inc. entered into a definitive agreement to acquire Sernova Biotherapeutics Inc in a merger of equals, reverse merger transaction.	CI
Jun. 17	Sernova's Autologous Islet Transplantation Gets Orphan Drug Designation For Type 3c Diabetes Prevention	MT
Jun. 11	Sernova Biotherapeutics Inc Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2026	CI
Apr. 22	Sernova Biotherapeutics Inc announced that it has received CAD 7.564399 million in funding	CI
Mar. 13	Sernova Biotherapeutics Inc Reports Earnings Results for the First Quarter Ended January 31, 2026	CI
Mar. 04	Sernova Biotherapeutics Inc announced that it expects to receive CAD 7.1 million in funding	CI
Dec. 19	Sernova Biotherapeutics Inc Reports Earnings Results for the Full Year Ended October 31, 2025	CI
Dec. 18	Sernova Biotherapeutics Inc Auditor Raises 'Going Concern' Doubt	CI
Nov. 12	Sernova Biotherapeutics Inc announced that it expects to receive CAD 5 million in funding	CI
25-09-23	Sernova Biotherapeutics Inc Appoints John L. Brooks III as Chair of the Board of Directors	CI
25-09-15	Sernova Biotherapeutics Inc Reports Earnings Results for the Third Quarter and Nine Months Ended July 31, 2025	CI
25-07-09	Sernova Partners With Eledon Pharmaceuticals to Advance Potential Functional Cure for Type 1 Diabetes	MT

Sernova Stock Toronto S.E.

Stocks

SVA

CA81732W1041

Medical Equipment, Supplies & Distribution

Valuation: Sernova

Chart: Sernova

Latest news: Sernova

Press Releases: Sernova

News in other languages: Sernova

Quotes and Performance

Price Extremes

Managers and Directors: Sernova

Medical Devices & Implants

Financials

Company Profile

Quotes

Analysts' Consensus

Quarterly revenue - Rate of surprise

Sep. 25	Sernova Biotherapeutics to Participate in Noble Capital Markets’ Emerging Growth Virtual Equity Conference	AQ
Sep. 11	Steven Sangha Announces Voting and Support Agreement for Sernova Biotherapeutics Inc.'s Proposed Business Combination with Seraxis Holdings, Inc.	NE
Sep. 10	Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference	AQ
Sep. 08	Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics	AQ
Jul. 21	A Diabetes Therapy Just Locked In Its Cell Supplier, and the Race to End Insulin Injections Is Heating Up	AQ

23-09-14	Sernova-Telefonkonferenz für Investoren, die ursprünglich für den 15. September geplant war, wird nun auf den 22. September verschoben
23-09-13	Sernova veranstaltet Telefonkonferenzen für Investoren zur Vorstellung der neu ernannten CEO und zur Bekanntgabe eines Updates zur Geschäftsentwicklung
23-05-03	AstraZeneca : accord de recherche avec le canadien Sernova
23-05-03	Sernova kündigt Forschungskooperation mit dem Pharmakonzern AstraZeneca an, um neuartige potenzielle Zelltherapie-Anwendungen zu untersuchen
23-04-10	Sernova präsentiert beim 2023 Cell & Gene Meeting on the Med der Alliance for Regenerative Medicine

1 week	+16.67%
1 month	-8.70%
3 months	-19.23%
6 months	-30.00%
Current year	-19.23%

1 week	0.08	0.12
1 month	0.08	0.15
3 years	0.08	0.82
5 years	0.08	2.22
10 years	0.08	2.87

Manager	Title	Age	Since
Jonathan Rigby CEO	Chief Executive Officer	58	2024-08-11
James Parsons DFI	Director of Finance/CFO	60	2024-10-10
David Burke IRC	Investor Relations Contact	-	2024-10-10

Director	Title	Age	Since
James Parsons BRD	Director/Board Member	60	2012-04-18
Steven Sangha BRD	Director/Board Member	-	2023-04-23
David Paterson BRD	Director/Board Member	-	2024-08-31

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERNOVA	-4.55%	+16.67%	-41.67%	-86.36%	27.82M
ABBOTT LABORATORIES	+0.84%	-3.74%	-26.69%	+1.85%	169B
MEDTRONIC PLC	-0.07%	-2.55%	-9.53%	+11.07%	110B
STRYKER CORPORATION	+0.90%	+1.13%	-24.83%	+0.58%	106B
ESSILORLUXOTTICA	-1.24%	-0.76%	-49.04%	-12.75%	73.87B
CENCORA, INC.	-0.24%	+0.69%	+0.16%	+72.58%	58.98B
HOYA CORPORATION	-0.86%	+2.96%	+13.57%	+59.50%	51.28B
BECTON, DICKINSON AND COMPANY	-0.71%	-3.82%	-7.72%	-31.41%	48.16B
IDEXX LABORATORIES, INC.	+0.12%	-0.17%	-18.21%	+20.29%	40.84B
DEXCOM, INC.	-1.01%	-1.45%	+28.48%	-9.72%	32.21B
Average	-0.25%	-0.86%	-13.55%	+2.56%	76.69B
Weighted average by Cap.	+0.03%	-1.30%	-16.36%	+10.12%

	2026 *	2027 *
Net sales	-	2.5M 1.75M 1.56M 1.45M 1.33M 169M 2.52M 17.6M 6.82M 86.19M 6.58M 6.44M 277M
Net income	-11.3M -7.93M -7.04M -6.57M -5.99M -762M -11.41M -79.55M -30.83M -390M -29.76M -29.12M -1.25B	-13.9M -9.75M -8.66M -8.09M -7.37M -937M -14.03M -97.85M -37.92M -479M -36.61M -35.81M -1.54B
Net Debt	-	-